These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18500428)

  • 1. B cell depletion and a T cell-targeted therapy allows to control the sudden onset of diabetes and lupus, without steroids.
    Ferraccioli G; Gremese E; De Santis M
    Acta Diabetol; 2008 Sep; 45(3):195-6. PubMed ID: 18500428
    [No Abstract]   [Full Text] [Related]  

  • 2. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
    Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
    Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
    Guzman Moreno R
    Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases.
    Lu TY; Jónsdóttir T; van Vollenhoven RF; Isenberg DA
    Ann Rheum Dis; 2008 Oct; 67(10):1493-4. PubMed ID: 18791057
    [No Abstract]   [Full Text] [Related]  

  • 5. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
    Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
    Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic lupus erythematosus in children: current and emerging therapies.
    Macdermott EJ; Adams A; Lehman TJ
    Lupus; 2007; 16(8):677-83. PubMed ID: 17711907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of rituximab in patients with systemic lupus erythematosus: an update.
    García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Galarza-Maldonado C; Sandoval-Cruz M; Zamudio-Huerta L; López-Colombo A; Cervera R
    Autoimmun Rev; 2009 Feb; 8(4):343-8. PubMed ID: 19036350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in lupus and beyond: the state of the art.
    Hughes G
    Lupus; 2009 Jun; 18(7):639-44. PubMed ID: 19433465
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study.
    Pego-Reigosa JM; Lu TY; Fontanillo MF; del Campo-Pérez V; Rahman A; Isenberg DA
    Rheumatology (Oxford); 2010 Apr; 49(4):691-6. PubMed ID: 20047982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel biological treatments for systemic lupus erythematosus: current and future modalities.
    Bezalel S; Asher I; Elbirt D; Sthoeger ZM
    Isr Med Assoc J; 2012 Aug; 14(8):508-14. PubMed ID: 22977972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New fields of cyclosporin A (sandimmun) application in rheumatology: treatment of systemic lupus erythematosus].
    Nasonov EL; Kliukvina NG; Shekshina SV; Nasonova VA
    Ter Arkh; 2000; 72(5):67-71. PubMed ID: 11109628
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pathogenesis, diagnosis and therapy of transitional (presystemic) forms of lupus erythematosus].
    Shaposhnikov OK; Gorbunov VF
    Vestn Dermatol Venerol; 1981 Nov; (11):4-7. PubMed ID: 6976049
    [No Abstract]   [Full Text] [Related]  

  • 13. Lymphoplasmapheresis for acute systemic lupus erythematosis (SLE).
    Gluck O; Dorson WJ
    Trans Am Soc Artif Intern Organs; 1984; 30():678. PubMed ID: 6533954
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of rituximab on resistant SLE disease including lung involvement.
    Reynolds JA; Toescu V; Yee CS; Prabu A; Situnayake D; Gordon C
    Lupus; 2009 Jan; 18(1):67-73. PubMed ID: 19074171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of systemic T-lymphocyte signal transduction inhibitors in the treatment of atopic keratoconjunctivitis.
    Anzaar F; Gallagher MJ; Bhat P; Arif M; Farooqui S; Foster CS
    Cornea; 2008 Sep; 27(8):884-8. PubMed ID: 18724148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study.
    Dhir V; Singh AP; Aggarwal A; Naik S; Misra R
    Lupus; 2009 Aug; 18(9):785-91. PubMed ID: 19578102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Systemic lupus erythematosus].
    Schröder JO; Euler HH
    Internist (Berl); 1993 Apr; 34(4):351-61. PubMed ID: 8486478
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical images: B cell depletion in the appendix following rituximab treatment.
    Paran D; Trej'o L; Caspi D
    Arthritis Rheum; 2006 Jul; 54(7):2151. PubMed ID: 16802352
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab.
    Ideguchi H; Ohno S; Takase K; Hattori H; Kirino Y; Takeno M; Ishigatsubo Y
    Rheumatology (Oxford); 2007 Oct; 46(10):1621-2. PubMed ID: 17726035
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.